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Abstract
Accumulating preclinical evidence indicates that early-life exposure to psychotropic medications
induce an anxiogenic-like behavioral profile in later life. However, these preclinical approaches
have been conducted primarily using male subjects. This is problematic since clinical data
indicates that women are more likely to be diagnosed with anxiety disorders than their male
counterparts, and thus, women are prescribed with psychotropic medications like fluoxetine
(FLX), a selective serotonin reuptake inhibitor (SSRI), at significantly higher rates. Therefore, the
goal of this Dissertation is to examine whether alterations in behavioral responses to anxietyeliciting stimuli are exhibited in adulthood, as a result of early-life FLX exposure. To do this,
female C57BL/6 mice were forced to consume FLX (250 mg/L in their drinking water) during
adolescence (postnatal days [PD] 35-49). After a 21-day washout period, at PD 70, they were
assessed for baseline shifts in anxiety-like behavior using the open field test (OFT), light/dark box
(LDB), and elevated plus maze (EPM) – tasks traditionally implemented to evaluate anxiogenic
responses in rodents. Since SSRI’s are prescribed long-term, and throughout the lifespan for the
management of anxiety disorders, we further evaluated if FLX re-exposure in adulthood (PD7084) would reverse such behavioral alteration (PD85). Lastly, because FLX mediates its therapeutic
effects by its ability to block the serotonin transporter (5-HTT), thus increasing global serotonin
and brain derived neurotropic factor (BDNF), the enduring effects of FLX on the 5HTT, as well
as the BDNF TrkB receptor and its downstream-related signaling molecules, were assessed within
the hippocampus and prefrontal cortex – brain regions implicated in mood-related disorders. We
found that adolescent exposure to FLX mediated a persistent anxiogenic profile per the OFT, LDB
and EPM, without changes in hippocampal or prefrontal cortex 5-HTT or TrkB receptor levels.
However, decreases in BDNF-related signaling markers, within both brain regions assessed, were
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evident in adulthood, as a function of adolescent FLX pretreatment. Also, as hypothesized, FLX
re-exposure in adulthood ameliorated the enduring SSRI-induced anxiety-related responses across
all behavioral tasks. Interestingly, FLX re-exposure, in adult female mice with juvenile FLX
history, normalized the decrease in BDNF-related signaling markers observed within the prefrontal
cortex, but not the hippocampus. Collectively, these data suggest that adolescent exposure to FLX
mediates neurobehavioral adaptations that endure into adulthood, which are indicative of a
generalized anxiogenic-like phenotype, and that this persistent effect is ameliorated by re-exposure
to FLX, in female C57BL/6 mice.
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Chapter 1: Introduction
Anxiety disorders are among the most commonly diagnosed psychiatric illnesses in
children and adolescents (Georgiades et al., 2019; Wittchen et al., 2011). Young people with
anxiety disorders display increased risk adverse outcomes, including academic failures, family and
social dysfunction, and develop comorbid mood-related illnesses such as major depression (Essau,
2003; Kim-Cohen et al., 2003). Interestingly, while selective serotonin reuptake inhibitor (SSRI)
medications were first introduced for the treatment of major depression, they also represent the
preferred pharmacotherapeutic approach for anxiety disorders (Pine, Helfinstein, Bar-Haim,
Nelson, & Fox, 2009; Rapoport, 2013). Indeed, SSRIs like fluoxetine (FLX) are effective for the
management of pediatric anxiety, with an overall response rate almost twice as great when
compared to placebo (Uthman & Abdulmalik, 2010). FLX’s mechanism of action is via the
blockade of serotonin reuptake transporters (5-HTT), indirectly increasing serotonin levels at the
synapse – a mechanism that is believed to underlie its therapeutic outcomes (Kiryanova & Dyck,
2014). In support of this notion, a genetic polymorphism that decreases the expression of 5-HTTs
is associated with anxiety and depression symptomatology in humans, thus providing a link for
the proposed action mechanism of SSRIs (Collier et al., 1996; Lesch et al., 1996).
Given the implication of serotonin in neurodevelopmental processes, such as neuronal
proliferation, differentiation, migration, and synaptogenesis (Gaspar, Cases, & Maroteaux, 2003;
Lv & Liu, 2017), as well as the link between 5-HTTs and mood-related illnesses (Nordquist &
Oreland, 2010), it is possible that ontogenic exposure to SSRI’s may lead to unexpected side
effects in later life. Indeed, at the preclinical level, accumulating studies indicate that juvenile FLX
exposure results in long-term changes in memory performance (Flores-Ramirez et al., 2019; Sass
& Wortwein, 2012), altered responsivity to despair measures and drugs of abuse (Flores-Ramirez
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et al., 2018; Iniguez et al., 2014), along with increased reactivity to anxiety-eliciting situations
(Ansorge, Zhou, Lira, Hen, & Gingrich, 2004; Homberg et al., 2011; Iniguez, Warren, & BolanosGuzman, 2010; Karpova, Lindholm, Pruunsild, Timmusk, & Castren, 2009). These enduring side
effects, collectively, highlight the need for caution when exposing young individuals to SSRI’s.
The neurobiological mechanisms underlying early-life SSRI-induced behavioral changes
in adulthood are not well understood (Homberg et al., 2011). However, some studies point to longterm FLX-induced alterations in 5-HTT’s and brain derived neurotropic factor (BDNF)-related
signaling molecules across different brain regions (Ansorge, Morelli, & Gingrich, 2008), including
the prefrontal cortex and hippocampus (Shrestha et al., 2014); structures that modulate affectrelated behavior (Duric et al., 2013; Iñiguez et al., 2019; Sierra-Fonseca et al., 2019; Williams et
al., 2020). Indeed, within these brain regions (see Fig. 1), SSRI’s reverse the stress-induced
decreases of BDNF and its receptor TrkB [BDNF-tropomyosin receptor kinase B (Yang et al.,
2020)], as well as the expression of ERK1/2 [extracellular-signal regulated kinase 1/2 (Duric et
al., 2010)], and the transcription factor CREB [cAMP response element-binding protein (Qi et al.,
2008)]; ultimately, facilitating neuronal growth and survival (Jiang & Salton, 2013).
It is noteworthy to highlight that the majority of clinical and preclinical studies that assess
FLX’s mechanism of action and efficacy, as well as its short- and long-term neurobehavioral
effects, have primarily utilized male subjects. The exclusion of females in such experimental
approaches is limiting and problematic, given the well-established difference between men and
women on drug efficacy, sensitivity, and safety (Agabio, Campesi, Pisanu, Gessa, & Franconi,
2016; Kokras & Dalla, 2017). In particular, because clinical data demonstrates that women are
more likely than men to be diagnosed with an anxiety-related disorder, a sex-difference that
becomes apparent by mid-adolescence (Beesdo, Knappe, & Pine, 2009; Keeton, Kolos, & Walkup,
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2009), and as a result, young girls are more likely to be prescribed with psychotropic medications
like FLX (Hoffmann, Glaeske, & Bachmann, 2014). To address this gap in the literature, the goal
of this dissertation is to examine whether juvenile FLX exposure mediates an anxiogenic
phenotype in adult female C57BL/6 mice, and if so, whether FLX re-exposure normalizes the
SSRI-induced anxiety-like behavioral response. Furthermore, to evaluate the enduring effects of
adolescent FLX-pretreatment, and its re-exposure in adulthood, on 5HTT’s and BDNF-related
signaling molecules (TrkB, ERK1/2, CREB) within the prefrontal cortex and hippocampus.

1.1 Aims of Dissertation
Aim 1: Examine the long-term effects of FLX exposure during adolescence (PD35-49) on baseline
shifts in anxiety-like behavior in adulthood (PD70) using female C57BL/6 mice.
Aim 2: Evaluate whether FLX re-exposure in adulthood will normalize alterations in anxiety-like
behaviors to control levels.
Aim 3: Assess changes in serotonin reuptake transporters (5-HTT), as well as BDNF-related
signaling molecules (TrkB, ERK1/2, CREB) in the hippocampus and prefrontal cortex, as
a function of juvenile FLX pretreatment, and its re-exposure in adulthood

1.2 Hypotheses
Previous work in male rodents has shown that exposure to FLX during adolescence leads
to enduring increases in responsivity to anxiety eliciting stimuli, later in life (Karpova et al.,
2009; Iñiguez et al., 2010). However, this approach has not been investigated in female rodents.
Thus, our central hypothesis is that adolescent FLX exposure in female mice can result in an
upward shift in baseline anxiety-like behavior, and that such phenotype can be reversed upon
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re-exposure of FLX treatment in adulthood. Furthermore, we hypothesize that FLX treatment
during adolescence will result in an enduring upregulation of 5-HTT’s, and a downregulation
of BDNF-signaling markers (TrkB, ERK1/2, CREB) in the prefrontal cortex and hippocampus,
brain regions that are involved in mood-related behavior. Lastly, that such persistent
neurobiological alterations in 5-HTT’s and BDNF-signaling will be normalized to control
levels upon re-exposure of FLX treatment in adulthood.
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Chapter 2: Methods
2.1 Animals
All procedures in this investigation complied with the Guide for the Care and Use of
Laboratory Animals (Council, 2003) and were approved by the Institutional Animal Care and Use
Committee at The University of Texas at El Paso (protocol: A-201609-1). Juvenile female
C57BL/6 mice arrived at our laboratory at postnatal day (PD)-28 from an outside vendor (Charles
River Laboratory; Hollister, CA). Mice were housed in polypropylene cages (3-4 per cage) bedded
with wood shavings, and with free access to food and water. The colony room was maintained at
temperature conditions between 21-23°C on a 12-hour light/dark cycle (lights on at 700 hour).
Mice were allowed to acclimate for 1-week before the start of the experiments.

2.2 Antidepressant Treatment
Fluoxetine hydrochloride (FLX; purchased from Spectrum Chemicals, Gardena, CA) was diluted
(250 mg/L) in water (vehicle; VEH), and administered ad libitum in the drinking water (changed
weekly) in light protected bottles (Model PC9RH8.5RD; Ancare, Bellmore, New York, USA). We
chose this route of administration to reduce animal attrition due to tissue necrosis associated with
post chronic intraperitoneal injections (Perrone, Chabla, Hallas, Horowitz, & Torres, 2004), and/or
FLX-induced constipation (Baek, Park, & Han, 2015). The concentration of FLX in the water was
selected based on previous work in male mice showing that this measure induces an
antidepressant-like behavioral profile in rodent models of despair (Flores-Ramirez et al., 2018),
and it yields a dose close to 25 mg/kg (Dulawa, Holick, Gundersen, & Hen, 2004) – considering
that females and adolescents display increased metabolic rates when compared to males and adults,
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respectively (Anderson, 2005; Hodes, Hill-Smith, Suckow, Cooper, & Lucki, 2010; Wegerer et
al., 1999).

2.3 Experimental Design
A schematic of our experimental approach is available in Figure 2. To evaluate whether
juvenile FLX exposure mediates an enduring anxiogenic-like outcome, along with altered
molecular changes in 5-HTT–BDNF signaling, adolescent female C57BL/6 mice were randomly
assigned to receive VEH or FLX for 15 consecutive days (PD35–49; Fig. 2A). This regimen was
chosen because it resembles the timeframe of development for human adolescence (Semple,
Blomgren, Gimlin, Ferriero, & Noble-Haeusslein, 2013). After a 21-day resting period (PD70),
separate cohorts of animals were either euthanized (for tissue collection) or tested in a variety of
behavioral tasks designed to assess anxiety-like behavior (Steimer, 2011) – the open field test
(OFT), light/dark box (LDB), and elevated plus maze (EPM). Because adolescent FLX exposure
increased reactivity to anxiety-inducing situations in adulthood across all behavioral paradigms
(Figs. 3A, 4A, and 5A), we designed a follow-up experiment (Fig. 2B) to evaluate whether FLX
re-exposure in adulthood would normalize the enduring FLX-induced molecular (Figs. 6A and
8A) and behavioral alterations observed. Specifically, juvenile mice received FLX or VEH for 15
days (PD35-49), matching FLX pretreatment during adolescence as in our initial experiment.
However, in this case, after the 21-day break, we re-exposed the animals to FLX for two weeks in
adulthood (PD71-84). Twenty-four hours after FLX re-exposure (PD85), separate groups of
animals were euthanized (for tissue collection) or tested on the OFT, LDB, and EPM (see Table
1 for experimental groups). A video tracking program (EthovisionXT; Noldus, Leesburg, VA) was
used to record behavior across all tasks.
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2.4 Animal Models for the Study of Anxiety
Preclinical models for the study of human disease aim to uncover and describe a biological
phenomenon that the animal species being studied has in common with humans. In other words,
animal models may provide an analogous aspect of the etiology, symptomatology, or
pharmacological treatment of the disease that is observed at the clinic (Belzung & Philippot, 2007;
Stein & Steckler, 2010). It is important to note that some aspects of human pathology may never
be recapitulated by animal models, such as guilty ruminations, suicidal ideation, and rapid speech
(Steimer, 2011). Nevertheless, they allow us to identify core aspects of behavior that may, in fact,
be representative of more complex symptomatology so that we can study the etiology of the
disease, as well as to develop efficacious pharmacological treatments (Gottesman & Gould, 2003;
Steimer, 2011). This is the case with animal models for the study of anxiety, since they recapitulate
a motivational conflict, in this case, inducing a decision-making process where making the wrong
choice may result in an unpleasant or fatal scenario to the organism, thus constituting a form of
psychological threat. For instance, when rodents are exploring a novel environment, a conflict
between curiosity and safety is usually present (Steimer, 2002, 2011). Here, it is important to
conceptually differentiate anxiety, which represents a response to a perceived threat, from fear, a
response to a real danger (Belzung & Philippot, 2007; Steimer, 2002). Applying this rubric, animal
models for the study of anxiety are useful to parse out the specific differences between these two
factors. Indeed, data collected from rodents demonstrate that while the amygdala plays a
significant function in conditioned fear, its definite role in anxiety is less clear, given that the
specific stimuli that trigger anxiogenic states are difficult to pinpoint (Davis, 1998; Davis, Walker,
& Lee, 1997). For example, lesions in the amygdala of adult rats mediate decreases in fear
responsivity, while anxiety-like behavior remains unaffected (Treit, Pesold, & Rotzinger, 1993).
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As such, there is a need to implement animal models to evaluate the specific contribution that other
brain regions involved in mood-related disorders, such as the hippocampus and prefrontal cortex,
play on responses to anxiety-inducing stimuli (Cominski, Jiao, Catuzzi, Stewart, & Pang, 2014;
Hare & Duman, 2020). This approach, in turn, will help uncover the neurobiology of anxiety
without the confounding factor of fear.

2.5 Open Field Test (OFT)
The OFT is commonly used to evaluate general locomotor activity, as well as exploratory
and anxiety-like behavior. In this test, under red lighting conditions (~30 Lux), rodents were placed
inside a white square box (40 cm in length × 40 cm in width × 40 cm in height) for a total of 5
min (Iniguez et al., 2010). Initially, rodents mostly explore the periphery of the box, but eventually
start exploring the center area (18 × 18 cm). Total distance traveled (cm) and time (sec) spent in
the center of the box were recorded. Less time spent in the center of the arena was interpreted as
an anxiogenic-like phenotype (Britton & Britton, 1981).

2.6 Light/Dark Box (LDB)
The LDB apparatus is comprised of two interconnected chambers (each 40 cm in length × 20 cm
in width × 35 cm in height). One chamber is black and enclosed, while the other one is white and
not enclosed (Model 63101; Stoelting, Wood Dale, IL). This behavioral paradigm takes advantage
of rodents’ innate instinct to avoid brightly illuminated areas, as well as to explore novel
environments, thus creating an internal conflict described as anxiety-like behavior (Bourin &
Hascoet, 2003; Montgomery & Monkman, 1955). Under red lighting conditions (~30 Lux), at the
start of the experiment, animals were placed in the dark compartment and allowed to move freely
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between the two chambers for 5 min. The latency to enter the light side of the apparatus, as well
as the total time spent in it, were the dependent variables. Less time spent in the light side of the
box was interpreted as an anxiogenic-like behavioral response.

2.7 Elevated Plus Maze (EPM)
This is a classic task used to evaluate anxiety-like behavior in rodents (Montgomery, 1955;
Sierra-Fonseca et al., 2019). Briefly, the animals were tested in a plus-shaped maze (under red
light conditions; ~30 Lux) that was elevated 50 cm from the floor. The apparatus has two open
arms (35 cm in length × 5 cm in width) and two closed arms (35 cm in length × 5 cm in width ×
15 cm in height; Model 60140; Stoelting, Wood Dale, IL). Animals were placed in the center of
the maze facing an open arm and allowed to freely explore the apparatus for 5 min. Time spent in
the closed arms, as well as total distance travelled (cm) were recorded (Iniguez et al., 2014). More
time spent in the closed arms was interpreted as an anxiogenic phenotype (Walf & Frye, 2007).

2.8 Western Blotting
Twenty-one days after the last day of SSRI treatment (for adolescent pre-exposure group)
or 24 hours after FLX re-exposure (for the adolescent pretreated and adult re-exposure group),
brains were rapidly extracted, and hippocampus and prefrontal cortex were microdissected on dry
ice, and stored at -80oC until assayed. Tissue was homogenized by sonication in 300µL of T-PER
buffer (ThermoFisher Scientific, #78510) supplemented with protease and phosphatase inhibitors
(Roche, #04693116001, #04906845001), and cleared by centrifugation at 14500 rpm for 10 min.
Supernatants were collected as total homogenate, and protein concentration was determined via
the bicinchoninic acid method (ThermoFisher Scientific, #23225), using bovine serum albumin as
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standard. Samples were dissolved in Laemmli buffer (BioRad, #1610737) containing 5% βmercaptoethanol (BioRad, #1610710), and equal amounts of hippocampal and cortical
homogenates were subjected to electrophoresis using 8-16% gradient pre-cast gels (BioRad,
#5678105), followed by electrotransfer onto polyvinylidene difluoride membranes (BioRad,
#1704159). The membranes were blocked in 5% non-fat dry milk dissolved in TBST (100 mM
Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20), and incubated overnight at 4°C with
primary antibodies (1:500) dissolved in blocking buffer. Membranes were washed with TBST and
incubated with appropriate horseradish peroxide-conjugated secondary antibodies (Cell Signaling
Technology, anti-rabbit 7074S, anti-mouse, #7076S; Abcam, anti-goat #ab6741). Protein bands
were visualized with the enhanced chemiluminescence technique, using the Clarity Western
Substrate kit (BioRad, #1705061). Membranes were subsequently stripped with Restore Stripping
Buffer (ThermoFisher Scientific, #46430) and re-probed with anti-tubulin antibody to serve as
loading control. Protein band densitometry was analyzed with ImageJ software (National Institutes
of Health).

2.9 Statistical Analysis
Separate groups of female mice were randomly assigned to receive VEH or FLX during
adolescence (long-term condition; groups 1, 2, 3, and 7 on Table 1). Additional groups of female
mice were assigned to receive VEH or FLX during adolescence and again in adulthood (reexposure condition; groups 4, 5, 6, and 8 on Table 1). Data were analyzed using two-tail Student's
t tests. Data are presented as mean ± SEM. Statistical significance was defined as p<0.05.
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Chapter 3: Results
3.1 Long-term Effects of Adolescent FLX Treatment, and its Re-exposure in Adulthood, on
the OFT
Figure 3A-B displays the effects of juvenile FLX exposure (PD35-49) on the OFT in
adulthood. A Student’s t test indicated that PD70 female mice pretreated with FLX (n=10)
displayed decreased time in the center zone of the arena when compared to VEH-pretreated (n=10)
controls (t18=2.91, p<0.05; Fig. 3A). No differences in locomotor activity (total distance traveled)
were observed between the groups (p>0.05; Fig. 3B).
Figure 3C-D displays the effects of FLX re-exposure (PD71-84) on the OFT in adult female
mice (PD85) with adolescent FLX history (PD35-49). A Student’s t test indicated that when
compared to VEH-pretreated controls (n=10), PD85 female mice with juvenile antidepressant
history and its re-exposure in adulthood (n=10) did not display differences in time spent in the
center zone of the OFT (p>0.05; Fig. 3C), or differences in total distance traveled during the 5 min
test (p>0.05; Fig. 3D).

3.2 Long-term Effects of Adolescent FLX Treatment, and its Re-exposure in Adulthood, on
the LDB test
Figure 4A-B shows the effects of adolescent FLX exposure (PD35-49) on the LDB in
adulthood (PD70). A Student’s t test revealed that when compared to VEH-pretreated controls
(n=10), FLX-pretreated mice (n=10) spent significantly less time in the light side of the apparatus
(t18=2.55, p<0.05; Fig. 4A). No differences in the latency to enter the lighted side of the box were
observed between the groups (p>0.05; Fig. 4B).
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Figure 4C-D displays the effects of FLX re-exposure (PD70-84) on the LDB in adult
female mice (PD85) with adolescent FLX history (PD35-49). A Student’s t test indicated that when
compared to VEH-pretreated controls (n=10), PD85 mice with juvenile FLX history and its reexposure in adulthood (n=10) did not differ in time spent in the lighted side of the apparatus
(p>0.05; Fig. 4C). No differences in latency to enter the lighted side of the box were observed
between the groups (p>0.05; Fig. 4D).

3.3 Long-term Effects of Adolescent FLX Treatment, and its Re-exposure in Adulthood, on
the EPM
Figure 5A-B shows the effects of adolescent FLX history (PD35-49) on the anxiogenic
environment of the EPM. A Student’s t test indicated that FLX-pretreated mice (n=10) spent
significantly more time in the closed arms of the maze, when compared to VEH-pretreated (n=10)
controls (t18=3.04, p<0.05; Fig. 5A). No differences in locomotor activity (distance traveled) were
observed between the groups (p>0.05; Fig. 5B).
Figure 5C-D displays the effects of FLX re-exposure (PD70-84) on the EPM in adult
female mice (PD85) with adolescent FLX history (PD35-49). A Student’s t test indicated that when
compared to VEH-pretreated controls (n=10), PD85 mice with juvenile FLX history and its reexposure in adulthood (n=10) did not differ in time spent in the closed arms of the EPM (p>0.05;
Fig. 5C). Lastly, no differences in distance traveled were observed between the groups (p>0.05;
Fig. 5D).

3.4 Long-term Effects of Adolescent FLX Treatment, and its Re-exposure in Adulthood, on
the Hippocampal Expression of 5-HTT’s and BDNF-related Signaling Molecules
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Figure 6A shows the enduring effects of adolescent FLX history (PD35-49) on the
phosphorylated levels of signaling markers that include ERK1/2, CREB, as well as total levels of
proBDNF and mBDNF within the hippocampus of PD70 female C57BL/6 mice. Student’s t test’s
indicated that, when compared to VEH-pretreated (n=10) controls, FLX-pretreated mice (n=10)
displayed significant decreases in ERK1 (t18=3.04, p<0.05), ERK2 (t18=2.64, p<0.05), as well as
CREB (t18=3.18, p<0.05), with no differences in total levels of proBDNF (p>0.05) or mBDNF
(p>0.05).
Figure 6B shows the effects of adolescent FLX exposure (PD35-49) and its re-exposure in
adulthood (PD70-84) on phosphorylated levels of ERK1/2, CREB, and total levels of proBDNF
and mBDNF within the hippocampus of PD85 female C57BL/6 mice. Here, animals with FLX
history displayed persistent decreases in phosphorylated levels of ERK1 (t18=3.01, p<0.05), ERK2
(t18=4.80, p<0.05), as well as CREB (t18=4.24, p<0.05), with no changes in total levels of
proBDNF or mBDNF (p>0.05, respectively).
Figure 7A shows the effects of adolescent FLX exposure (PD35-49) on total levels of
signaling markers that include ERK1/2, CREB, TrkB, and 5-HTT within the hippocampus of PD
70 female C57BL/6 mice. No differences in the total levels of ERK1/2, CREB, TrkB, or 5-HTT
(p>0.05, respectively) were observed in the hippocampus of adult female mice, as a function of
FLX exposure during adolescence.
Figure 7B shows the effects of adolescent FLX exposure (PD35-49) and its re-exposure on
total protein levels of signaling markers that include ERK1/2, CREB, TrkB, and 5-HTT within the
hippocampus of PD85 female C57BL/6 mice. No differences in the total levels of ERK1, ERK2,
CREB, TrkB, or 5-HTT (p>0.05, respectively) were apparent in the hippocampus of adult female
mice, as a function of juvenile FLX exposure and adult re-exposure.

13

3.5 Long-term Effects of Adolescent FLX Treatment, and its Re-exposure in Adulthood, on
the Expression of 5-HTT’s and BDNF-related Signaling Molecules in the Prefrontal Cortex
Figure 8A shows the enduring effects of adolescent FLX history (PD35-49) on
phosphorylated levels of signaling markers that include ERK1/2, CREB, as well as total levels of
proBDNF and mBDNF within the prefrontal cortex of PD70 female C57BL/6 mice. Student’s t
test’s indicated that, when compared to VEH-pretreated (n=10) controls, FLX-pretreated mice
(n=10) displayed significant decreases in ERK2 (t18=5.07, p<0.05), CREB (t18=3.99, p<0.05),
proBDNF (t18=2.44, p<0.05) and mBDNF (t18=2.50, p<0.05). No differences in phosphorylation
levels of ERK1 were noted between the groups (p>0.05).
Figure 8B shows the enduring effects of adolescent FLX exposure (PD35-49) and its reexposure in adulthood (PD70-84) on phosphorylated levels of ERK1/2, CREB, and total protein
levels of proBDNF and mBDNF within the prefrontal cortex of PD85 female C57BL/6 mice. Here,
no differences in phosphorylated levels of ERK1/2, CREB, or total levels of proBDNF (p>0.05,
respectively) were observed, but a significant increase in mBDNF (t18=2.57, p<0.05) was apparent
in the prefrontal cortex of adult female mice with juvenile FLX history and re-exposure in
adulthood when compared to VEH controls.
Figure 9A shows the effects of adolescent FLX exposure (PD35-49) on total protein levels
of signaling markers that include ERK1/2, CREB, TrkB, and 5-HTT within the prefrontal cortex
of PD70 female C57BL/6 mice. No differences in the total levels of ERK1/2, CREB, TrkB, or 5HTT (p>0.05, respectively) were observed in the adult prefrontal cortex of female mice, as a
function of FLX history during adolescence.
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Figure 9B shows the effects of adolescent FLX exposure (PD35-49) and its re-exposure in
adulthood (PD70-84) on total protein levels of signaling markers that include ERK1/2, CREB,
TrkB, and 5-HTT within the prefrontal cortex of PD85 female C57BL/6 mice. Here, no differences
in total protein levels of ERK1/2, CREB, TrkB, or 5-HTT (p>0.05, respectively) were apparent in
the prefrontal cortex of PD85 female mice, as a function of juvenile FLX exposure and its reexposure in adulthood.
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Chapter 4: Discussion
4.1 Summary
The goal of this Dissertation was to evaluate if juvenile FLX exposure induces a long-term
change in baseline responses to anxiety-inducing environments, and if so, whether its re-exposure
in adulthood would ameliorate this anxiogenic-like phenotype. Furthermore, to assess the effects
of adolescent FLX pre-treatment, and its re-exposure in adulthood, on 5-HTT-BDNF-related
signaling markers (Fig. 1), within the hippocampus and prefrontal cortex of female C57BL/6 mice.
To accomplish this, female mice were exposed to FLX in their drinking water (VEH), during the
adolescent stage of development (PD35-49). Animals were then given a 21-day washout period,
until they reached adulthood (PD70), and were then evaluated on behavioral responses to the OFT,
LDB, and EPM (Fig. 2A). We found that juvenile FLX history resulted in a persistent anxiogeniclike profile across all behavioral tasks (Figs. 3A, 4A, 5A), without alterations in 5-HTTs or BDNF
(TrkB) receptors within the hippocampus (Fig. 7A) or prefrontal cortex (Fig. 9A). Interestingly,
enduring brain region-specific downregulation patterns of phosphorylated ERK1/2, and CREB,
without changes in their total protein levels, were observed across the hippocampus (Fig. 6A and
7A, respectively) and prefrontal cortex (Fig. 8A and 9A, respectively), as a function of juvenile
FLX pretreatment. While downregulation of pERK2 and pCREB were evident in both brain
regions assessed, there were also decreases in total protein of proBDNF and mBDNF within the
prefrontal cortex (Fig. 8A) – highlighting that adolescent FLX history impacts these brain regions
in a similar, yet, unique way.
Given that FLX history resulted in a long-term anxiogenic-like behavioral phenotype,
along with downregulation of intracellular ERK-CREB-BDNF signaling within brain regions
associated with the etiology of mood related disorders (Gourley et al., 2008; Li et al., 2018; Qi et
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al., 2008), we followed up with an additional experiment that evaluated whether adult FLX reexposure would ameliorate the neurobehavioral effects observed (Fig 2B). In this case, separate
groups of adult female mice (with juvenile FLX history) were re-exposed to FLX in adulthood
(PD70-84), and were evaluated on their reactivity to the OFT, LDB, and EPM (PD85). We found
that FLX re-exposure normalized responses to anxiety-inducing situations back to control levels,
across all three behavioral tests (see Figs. 3C, 4C, and 5C). Interestingly, FLX re-exposure in
adulthood did not rescue the early-life FLX-induced downregulation of pERK1/2 and pCREB
within the hippocampus (Fig. 6B). However, within the prefrontal cortex, FLX re-exposure
restored pERK, pCREB, and proBDNF back to normal levels, while also increasing mBDNF
protein within this brain region (Fig. 8B). Lastly, no differences in 5-HTT or BDNF’s TrkB
receptors, in either brain region (Figs. 7B and 9B), were observed as a function of juvenile FLX
history and its re-exposure in adulthood.

4.2 Adolescent FLX Treatment Mediates an Enduring Anxiogenic-like Behavioral Profile
that is Rescued by FLX Re-exposure in Adulthood
The results of the present study highlight that exposure to the SSRI FLX, in juvenile female
mice, leads to a long-term anxiogenic behavioral profile in adulthood, per the OFT, LDB, and
EPM tests, without alterations in general locomotor activity (Figs. 3B and 5B). Specifically, when
compared to the VEH-pretreated groups, adult female mice with FLX history, spent less time in
the center of the OF and the lighted area of the LDB, while spending more time inside the closed
arms of the EPM (see Figs. 3A, 4A, 5A) – a behavioral response that, collectively, indicates that
SSRI pre-treatment mediates a long-term upward shift in baseline responses to anxiety-inducing
situations. Of note, these results support previous work adopting similar behavioral tasks where
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early-life FLX induced an anxiogenic-like phenotype in adult male rodents (Ansorge et al., 2004;
Homberg et al., 2011; Iniguez et al., 2010; Karpova et al., 2009); yet here, we expand these findings
to female mice.
Developmental exposure to FLX, mediating an anxiogenic phenotype in adulthood, is an
interesting paradoxical finding since this SSRI is commonly prescribed for the management of
anxiety disorders (Baldwin, Woods, Lawson, & Taylor, 2011; Gentile, 2014). Indeed, under
normal conditions, adult rodents chronically exposed to FLX display anxiolytic-like behavior
(Dulawa et al., 2004), or no long-term behavioral alterations at all (Song et al., 2019), mimicking
human responses (Yohn et al., 2020). Such paradoxical behavioral profile, as a function of
developmental SSRI exposure, highlights that adolescence is a vulnerable window for later-life
adverse side effects. Indeed, this long-term anxiogenic-like behavioral response may, in fact, be
the result of FLX-induced alterations in brain circuitry regulating anxiogenic responses via chronic
disruptions in serotonin functioning. Specifically, the side effects of juvenile FLX exposure are
delayed, outlasting the exposure window of the drug itself, a concept described as neuronal
imprinting (Andersen, 2003). Therefore, adolescent exposure to FLX may, indeed, be operating
similar to an environmental insult exerting persistent neurobehavioral changes that make their
presence known in adulthood (Andersen, 2003) – consequently, leaving the organism in need of
pharmacological intervention to ameliorate these unwanted side effects (Flores-Ramirez et al.,
2018). For this reason, we also evaluated whether FLX re-exposure in adulthood, in female mice
with juvenile FLX history, would reverse the behavioral responses observed on the OFT, LDB,
and EPM (see Fig. 2B). As hypothesized, re-exposure to FLX in adulthood normalized responses
across all behavioral tests (Figs. 3C, 4C, 5C). Of note, this enduring anxiogenic profile, wherein
FLX rescues early life SSRI-induced alterations to anxiety-inducing situations, has been reported
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previously in male mice (Karpova et al., 2009) and rats (Iniguez et al., 2010); highlighting that
early-life antidepressant treatment renders both males and females in need of subsequent
antidepressant re-exposure to normalize responses to anxiety-inducing stimuli.

4.3 Adolescent FLX Treatment, and its Re-exposure in Adulthood, Alters Intracellular ERKCREB-BDNF signaling within the Hippocampus and Prefrontal Cortex
The molecular mechanisms by which juvenile FLX exposure mediates persistent
anxiogenic-like responses in adulthood, and normalizes them upon re-exposure, are currently
unknown. Acutely, FLX indirectly increases serotonin levels, via the blockade of 5-HTT’s
(Kiryanova & Dyck, 2014). This global increase in serotonin tone, after chronic exposure,
ultimately leads to serotonin receptor alterations (Hensler, 2003; Hrdina & Vu, 1993) and
elevations in BDNF-related signaling molecules (Nibuya, Nestler, & Duman, 1996). For this
reason, we evaluated protein levels of 5-HTT’s and BDNF’s TrkB receptor, as well as key down
stream signaling molecules (ERK-CREB-BDNF) within the hippocampus and prefrontal cortex of
adult female mice with juvenile FLX pretreatment. Interestingly, we found that adolescent FLX
pre-exposure did not influence the expression of 5-HTT’s or TrkB receptors in either brain region
assessed (Figs. 7A and 9A). This was surprising given that previous studies, in male animals, have
shown that developmental exposure to FLX mediates persistent alterations in the expression of 5HTT’s, as well as BDNF’s receptor, TrkB, within these brain regions (Bouet et al., 2012; Karpova
et al., 2009; Shrestha et al., 2014; Wegerer et al., 1999). As such, the present null data on 5-HTT’s
and TrkB receptors in female mice, along with the previous work in male animals evaluating these
membrane-bound markers, indicate that early-life exposure to FLX exerts its persistent anxiogenic
effects via potential alterations in downstream membrane mechanisms between the sexes. In other
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words, that early-life antidepressant exposure mediates divergent lasting changes in membrane
bound receptors (5-HTT and TrkB) that are male, but not female-specific, as a function of juvenile
FLX history. Therefore, we also evaluated intracellular hippocampal and prefrontal cortex ERKCREB-BDNF markers, given that these downstream signaling molecules have also been found to
modulate affect-related behavior in intact adult rodents (Z. Y. Chen et al., 2006; Li et al., 2018; Qi
et al., 2008; Sierra-Fonseca et al., 2019). Here, we found that juvenile FLX pre-treatment resulted
in a long-term decrease in the phosphorylation of ERK2 and CREB within both brain regions (Fig.
6A and 8A, respectively), with additional decreases in BDNF (both proBDNF and mBDNF) within
the prefrontal cortex (Fig. 8A); molecular changes that likely underlie the anxiogenic-like
behavioral phenotype observed (Figs. 3A, 4A, 5A). Indeed, under normal conditions, acute
decreases in BDNF (Castren & Kojima, 2017), ERK (Qi et al., 2009), and CREB (A. C. Chen,
Shirayama, Shin, Neve, & Duman, 2001) induce anxiety-like responses in preclinical models of
anxiety (Barrot et al., 2002; Carlezon, Duman, & Nestler, 2005), with FLX rescuing these
behavioral alterations via enhancement in the expression of these proteins. Importantly, this effect
is observed in both animal models (Qi et al., 2008), as well as in postmortem studies of patients
who underwent SSRI treatment (Dowlatshahi, MacQueen, Wang, & Young, 1998; Yamada,
Yamamoto, Ozawa, Riederer, & Saito, 2003), thus providing construct validity to our preclinical
findings.
Because adolescent SSRI exposure (PD35-49) resulted in the downregulation of
hippocampal and prefrontal cortex ERK-CREB-BDNF signaling 21-days post treatment, we also
evaluated how FLX re-exposure (PD70-84) would influence these signaling molecules in
adulthood (PD85). In this case, we found that adult FLX re-exposure did not rescue the juvenile
SSRI-induced hippocampal downregulation of pERK1/2 and pCREB at PD85 (Fig. 6B). However,
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within the prefrontal cortex, adult FLX re-exposure normalized ERK, CREB, and proBDNF
molecules, while significantly increasing mBDNF, when compared to controls (Fig. 8B). Taken
together, these data highlight that the prefrontal cortex, but not the hippocampus, underlies FLX’s
mechanism to exert its anxiety-reducing effects in adult female mice with juvenile FLX history.
Furthermore, these results suggest that exposure to FLX mediates lasting changes of neuronal
processes when administered in vulnerable periods of development, such as adolescence (Olivier,
Blom, Arentsen, & Homberg, 2011), and that re-exposure to FLX in adulthood normalizes
functioning via enhancement of prefrontal cortex plasticity processes. Supporting this notion, FLX
reactivated neuronal plasticity and normalized functioning within the visual cortex of adult male
mice that displayed visual circuitry imbalances, as a function of visual deficits during early periods
of development. Likewise, improvements in the visual system were the result of FLX’s ability to
increase the expression of BDNF within this system (Maya Vetencourt et al., 2008), as in the
present results within the prefrontal cortex (Fig. 8B).

4.4 Limitations
A limitation of this investigation is that we did not experimentally account for the role of
the estrous cycle on the anxiogenic behavioral responses across our pharmacological conditions.
Particularly, because in naturally cycling adult female C57BL/6 mice, FLX’s anxiolytic effects on
the EPM are dependent on the estrus phase of the cycle (Yohn et al., 2020). As such, future
investigations are needed to dissect the relationship between the specific stages of the estrous
cycle, in adulthood, as a function of juvenile FLX pretreatment. Furthermore, given that FLX was
freely administered in the drinking water, the exact FLX plasma levels underlying the enduring
anxiogenic profile observed in this investigation are currently not known. While, the selected FLX
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regimen (250 mg/L) results in a dose that approximates 25 mg/kg (Dulawa et al., 2004) we must
note that juveniles metabolize at higher rates than adult organisms. As such, it is possible that using
the same dose of FLX resulted in different plasma concentrations during adolescence (preexposure), versus adulthood (re-exposure). Yet, we must note the dose selected results in a
therapeutic-like effect in traditional preclinical models of despair in both adolescent and adult
female C57BL/6 mice (Flores-Ramirez et al., 2018).

4.5 Functional Implications
While FLX is regarded as a safe and efficacious pharmacological treatment for pediatric
anxiety disorders, the data from the present study uncovered enduring anxiogenic-like
consequences, along with hippocampal and prefrontal cortex molecular alterations, as a function
of its exposure during adolescence. Interestingly, our results demonstrate that this persistent SSRIinduced anxiety-like response, in female C57BL/6 mice, can be rescued by re-exposure to FLX in
adulthood – an effect that is likely explained by FLX’s ability to reverse the long-lived SSRIinduced molecular changes in the adult prefrontal cortex, but not the hippocampus. As such, these
findings have important clinical implications, since they suggest that juvenile FLX exposure may
render females reliant on SSRI treatment for sustained normalcy in later life – implicating that
once pharmaceutical treatment begins, potential lifetime management with antidepressants will
ensue.
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Table 1. Experimental Groups
Group Treatment
n
Age

Interval

Procedure I

Procedure II

Data

1

VEH
FLX

10
10

PD35-49

21-days

OFT
(PD70)

–

Fig. 3A-B

2

VEH
FLX

10
10

PD35-49

21-days

LDB
(PD70)

–

Fig. 4A-B

3

VEH
FLX

10
10

PD35-49

21-days

EPM
(PD70)

–

Fig. 5A-B

4

VEH
FLX

10
10

PD35-49

21-days

VEH or FLX
Re-exposure
(PD70-84)

OFT (PD85)

Fig. 3C-D

5

VEH
FLX

10
10

PD35-49

21-days

VEH or FLX
Re-exposure
(PD70-84)

LDB (PD85)

Fig. 4C-D

6

VEH
FLX

10
10

PD35-49

21-days

VEH or FLX
Re-exposure
(PD70-84)

EPM (PD85)

Fig. 5C-D

VEH

10

FLX

10

PD35-49

21-days

Western blot

–

Fig. 6-9A

VEH
FLX

10
10

21-days

VEH or FLX
Re-exposure
(PD70-84)

Western blot

Fig. 6-9B

7

8

PD35-49

EPM, elevated plus maze; FLX, fluoxetine; LDB, light-dark box; OFT, open field test; PD,
postnatal day; VEH, vehicle.

35

Figure 1. Molecular effects of fluoxetine (FLX) on BDNF-ERK1/2-CREB signaling. FLX
indirectly increases serotonin tone by blocking the serotonin transporter (5-HTT) at the presynaptic
terminal. Serotonin (5-HT) binds to its metabotropic receptors, leading to the activation of the
ERK1/2 kinase. ERK1/2 then translocates into the nucleus, and phosphorylates (p) the
transcription factor CREB. This, in turn, increases the transcription of proBDNF, the precursor of
BDNF, which results in the upregulation of mBDNF, the mature version of this growth factor. As
a result, vesicular packaging and traficking processes initiate, ultimately releasing BDNF into the
synaptic cleft, where BDNF activates its receptor, TrkB, leading to cell growth and survival.
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Figure 2. Timeline of juvenile fluoxetine (FLX) treatment and experimental procedures. A)
Postnatal day (PD)-28 female C57BL/6 mice arrived to our animal colony. One week later (PD35),
they were randomly assigned to receive FLX in their drinking water (250 mg/L) for 15 consecutive
days (PD35-49), or water alone (vehicle, VEH). After a 21-day washout period (PD70), separate
groups of mice were euthanized for tissue extraction or tested on the open field test (OFT),
light/dark box (LDB), or elevated plus maze (EPM). B) Separate groups of PD28 mice arrived to
our animal colony. One-week later (PD35) they were exposed to VEH or FLX in their drinking
water (PD35-49). After a 21-day washout period (PD70), FLX was re-administered for two
additional weeks (PD70-84). Twenty-four hours after FLX re-exposure (PD85), mice were either
euthanized for tissue collection or tested on the OFT, LDB, or EPM.
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Open Field Test
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C)
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Re-exposure (PD85)

1800
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Figure 3. Long-term effects of juvenile fluoxetine (FLX) treatment, and its re-exposure in
adulthood, on the open field test. A) FLX pretreatment during adolescence (PD35-49) resulted in
a decrease in the time spent in the center area of the open field arena at PD70 (Long-Term). B)
FLX pretreatment did not influence total distance traveled during the 5-min session of the open
field test. C) Re-exposure to FLX in adulthood (PD70-84) ameliorated the long-lasting anxiogeniclike effect of adolescent FLX pre-exposure, as no differences in total time spent in the center
between the groups were observed. D) At PD85, no differences in distance traveled were apparent
between the experimental groups. Data are presented as mean ± SEM. *p<0.05.
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Figure 4. Long-term effects of juvenile fluoxetine (FLX) treatment, and its re-exposure in
adulthood, on the light/dark box. A) Juvenile FLX pretreatment (PD35-49) led to a significantly
decreased time spent in the lighted-side of the light/dark box at PD70 (Long-Term), when
compared to water (VEH)-pretreated controls. B) When compared to VEH-pretreated controls,
juvenile FLX pretreatment did not influence the time it took the animals to first enter the lightedside of the apparatus. C) FLX re-exposure in adulthood (PD70-84) ameliorated the long-lasting
anxiogenic-like effect of juvenile FLX pretreatment, as no differences in total time spent in the
center between the groups were observed. D) At PD85, no differences in the time it took for
animals to first enter the lighted side of the apparatus were apparent between the experimental
groups. Data are presented as mean ±SEM. *p<0.05.
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Figure 5. Long-term effects of juvenile fluoxetine (FLX) treatment, and its re-exposure in
adulthood, on the elevated plus maze. A) Adolescent FLX pretreatment (PD35-49) resulted in a
significant increase in time spent in the closed arms of the maze at PD70 (Long-Term), when
compared to water (VEH)-treated controls. B) No differences in distance traveled during the 5min test were observed between the groups. C) Re-exposure of FLX in adulthood (PD70-84)
ameliorated the long-lasting anxiogenic effect of juvenile FLX pre-exposure since no differences
in total time spent in the closed arms were noted between the groups (PD85). D) No differences in
distance traveled were observed between the experimental groups. Data are presented as mean ±
SEM. *p<0.05.
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Figure 6. Long-term effects of juvenile FLX treatment, and its re-exposure in adulthood, on
phosphorylated levels of ERK1, ERK2, CREB, and total (t) levels of proBDNF and mBDNF in
the hippocampus of female C57BL/6 mice. A) Adolescent FLX pretreatment (PD35-49)
significantly decreased pERK1, pERK2, and pCREB at PD70 (Long-Term), when compared to
water (VEH)-treated controls. B) Re-exposure to FLX in adulthood (PD70-84), in female mice
with adolescent FLX history, decreased phosphorylated (p) levels of ERK1, ERK2, and CREB,
with no differences in total proBDNF or mBDNF, 24 hours after the end of treatment (PD85). Data
are presented as mean ± SEM. *p<0.05.
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Figure 7. Long-term effects of juvenile FLX treatment, and its re-exposure in adulthood, on total
(t) protein levels of ERK1, ERK2, CREB, TrkB, and 5-HTT in the hippocampus of female
C57BL/6 mice. A) No differences in total levels of ERK1, ERK2, CREB, TrkB, or 5-HTT were
observed in adult (postnatal day [PD] 70) female mice pretreated with FLX during adolescence
(PD35-49), when compared to water (VEH)-pretreated controls. B) Similarly, no differences in
the total protein levels of ERK1, ERK2, CREB, TrkB, or 5-HTT were evident on PD85, as a
function of juvenile FLX exposure (PD35-49) and re-exposure in adulthood (PD70-84). Data are
presented as mean ± SEM.
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Figure 8. Long-term effects of juvenile FLX treatment, and its re-exposure in adulthood, on
phosphorylated (p) levels of ERK1, ERK2, CREB, and total (t) levels of proBDNF and mBDNF
in the prefrontal cortex of female C57BL/6 mice. A) Adolescent FLX pretreatment (postnatal day
[PD] 35-49) resulted in significant decreases in pERK2, pCREB, t-proBDNF, and t-mBDNF at
PD70 (Long-Term), when compared to water (VEH)-pretreated controls. B) Re-exposure to FLX
in adulthood (PD70-84) normalized the phosphorylated levels of ERK2, CREB, and total levels of
proBDNF, and significantly increased total levels of mBDNF, 24 hours after the end of
antidepressant re-exposure (PD85). Data are presented as mean ± SEM. *p<0.05.
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Figure 9. Long-term effects of juvenile fluoxetine (FLX) treatment, and its re-exposure in
adulthood, on total (t) levels of ERK1, ERK2, CREB, TrkB, and 5-HTT in the prefrontal cortex of
female C57BL/6 mice. A) No significant differences in total protein levels of ERK1, ERK2,
CREB, proBDNF, or mBDNF were apparent in adulthood (PD70), as a function of adolescent
(postnatal day [PD] 35-49) FLX or water (VEH)-pretreatment. B) Similarly, no differences in the
total levels of these proteins were evident on PD85, as a function of juvenile FLX treatment (PD3549) and its re-exposure in adulthood (PD70-84). Data are presented as mean ± SEM.
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